Moehler, M., Maderer, A., Thuss‐Patience, P., Brenner, B., Meiler, J., Ettrich, T. J., . . . Lorenzen, S. (2020). Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: A prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
Tohutoru Kātū Chicago (17th ed.)Moehler, Markus, et al. Cisplatin and 5-fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-label, Randomised Phase III AIO/EORTC Trial (POWER). 2020.
Tohutoro MLA (9th ed.)Moehler, Markus, et al. Cisplatin and 5-fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-resectable, Advanced or Metastatic Oesophageal Squamous Cell Cancer: A Prospective, Open-label, Randomised Phase III AIO/EORTC Trial (POWER). 2020.